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SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comby 20% indicating reduction of LV ﬁlling pressure, the LVEF by Teicholz increased
from 39% up to 45% (15%), by Simpson decreased from 45% to 40% by reducing
8.8%, cardiac output decreased from 2.61 l/min to 2.31 l/min during balloon
inﬂation.
Conclusions: We are reporting the ﬁrst experience in humans of a new method for
intermittent preload reduction in patients with CHF. The beneﬁcial hemodynamic and
echocardiographic changes obtained in this patient suggest that this new procedure
may play role in the treatment of patients with CHF. Large studies are needed to
further evaluate this new procedure.
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Background: There is a paucity of data regarding the feasibility, safety and efﬁcacy
of fetal pulmonary valvuloplasty (FPV) for pulmonary atresia or stenosis with intact
interventricular septum (PA/PS/IVS) and evolving hypoplastic right heart syndrome
(HRHS) diagnosed in-utero. We report in-utero and post natal outcomes of this
procedure.
Methods: FPV was performed under maternal spinal anesthesia and fetal general
anesthesia by a multi-disciplinary team under echo monitoring. A 15 cm long 17 G
Chiba needle was used to access the apex of the RV. The pulmonary valve (PV) was
perforated (when atretic) either with the needle or using a stiff coronary wire. Pre-
mounted systems with coronary balloons (1.2-1.5 times the valve annulus) over
coronary wires were advanced.
Results: From 01/08, 10 fetuses (6 PS/ 4 PA; mean age: 27  2 weeks) underwent
11 procedures. There were 2 failures 2. One had a successful repeated procedure
2 weeks afterwards. There were no maternal complications. The valve was suc-
cessfully crossed and dilated in 9 with echo evidence of forward ﬂow and pulmonary
insufﬁciency. Ductal spasm was observed in 4. Pericardial effusion requiring
drainage was observed in all but one patient. One patient was born at elsewhere and
underwent a BTT shunt and is now 3 months. Two fetuses are still in-utero. Six
patients were born at our center and underwent neonatal pulmonary valvuloplasty
and ductal stenting and were followed over a median post-natal period of 12 months
(6-48). In these patients there was a signiﬁcant and progressive increase in RV size
(Z value of the TV, RV length) from the initial in-utero to the last echo assessment
and all achieved an eventual BVC and spontaneous closure of the ductal stent with
Sats > 90%.
Conclusions: FPV followed by neonatal valvuloplasty and ductal stenting was an
effective means to achieve adequate RV growth and a BVC in fetuses with PA/PS/IVS
and evolving HRHS. FPV is technically demanding and frequently results in peri-
cardial effusion requiring drainage. The procedure seems to be safe to the mother.
More patients are needed to draw stronger conclusions.
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Background: Degradation of bioabsorbable stents (BAS) has been shown to allow
restoration of the treated segment’s plasticity and reactivity to those resembling a non-
stented artery, a desirable feature unattainable with metallic stents (BMS). We aimed
to evaluate by OCT the long term dynamic changes in arterial geometry in response to
a novel non-drug eluting BAS as compared to BMS.
Methods: Thirty-ﬁve coronary arteries of 13 swine received BAS (Amaranth Medical,
Mountain View, CA n¼22) or BMS (Liberte Boston Scientiﬁc, Natick, MA n¼13).
Optical coherence tomography (OCT) was done at day 0, day 28 (BAS, n¼22; BMS,
n¼13), 1 year and 2 years (BAS, n¼6; BMS, n¼4).
Results: The lumen areas of reference segments increased over time, but less for the
BMS-caged segments (Day 0¼6.11.8mm2, 2 Years¼10.62.9mm2) than for the
BAS-treated arteries (Day 0¼6.71.9mm2, 2 Years¼12.10.4mm2). BMS showed
lumen area loss at 28 days as expected due to neointimal formation, and then minimal
lumen area variance over time up to 2 years (Day 0¼6.791.7mm2, 2
Years¼6.782.25mm2). In contrast, in BAS the early lumen area loss present at 28
days inverted into lumen gain that corresponded with the scaffold mechanics paral-
leling the artery growth and allowing the treated segment to remodel (Day
0¼7.310.9mm2, 2 Years¼9.711.58mm2, Figure).B126 JACC Vol 64/11/Suppl B jConclusions: Restoration of the treated segment’s ability to grow and remodel, with
late lumen area gain as a consequence, appear to be a reproducible and inherent
pattern of non-drug eluting bioabsorbable stent behavior in the porcine coronary
model.
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Background: We designed the ﬁrst poly-L-lactic acid XINSORB scaffold in China.
Long-term morphological results of this kind of scaffold were explored in a porcine
coronary model.
Methods: XINSORB scaffold (3.0mm in diameter and 15mm in length) were
implanted into porcine coronary arteries with a reference vessel diameter ranging from
2.5 to 2.8mm, using a 1.1:1 stent-to-artery ratio. Angiogram and optical coherence
tomography (OCT) test were performed after implantation and at 1, 3, 12, and 18-
month follow-up.
Results: Total 28 mini pigs were enrolled and 56 scaffolds were deployed. At 1, 3, 12,
and 18-month, 8, 8, 10, and 10 scaffolds were examined respectively. Angiogram after
procedure showed that proximal, in-scaffold, and distal minimal luminal diameter
were 2.930.28mm, 2.780.26mm and 2.730.30mm. The corresponding percent-
age of diameter stenosis (%DS) was 5.74.0%, 7.04.1% and 6.74.1% respec-
tively. At 1-month follow-up, proximal, in-scaffold, and distal late luminal loss (LLL)
of scaffold were 0.530.41mm, 0.680.42mm and 0.650.24mm, while %DS were
9.57.7%, 17.616.8% and 10.57.4%. At 3-month, proximal, in-scaffold, and
distal LLL were 0.230.48mm, 0.770.48mm and 0.110.35mm, while %DS were
14.59.4%, 31.913.6% and 5.43.6%. At 12-month, proximal, in-scaffold, and
distal LLL were -0.130.45mm, 0.280.41mm and 0.180.48mm, while %DS were
2.42.9%, 14.19.1% and 8.68.7%. At 18-month, proximal, in-scaffold, and distal
LLL were 0.370.57mm, 0.090.31mm and -0.010.41mm, while %DS were
3.94.6%、13.77.3% and 6.95.2%. OCT demonstrated that luminal area, scaffold
area, neointimal area and percentage of area stenosis were 5.951.63mm2,
8.081.16mm2, 2.120.67mm2 and 25.810.6% at 1 month, 4.020.96mm2,
7.910.53mm2, 2.890.45mm2 and 37.99.7% at 3 month, 5.960.82mm2,
8.090.74mm2, and 2.070.36mm2 and 24.17.3% at 12 month and
6.840.77mm2, 8.740.82mm2, 1.940.56mm2 and 19.76.9% at 18 month.
Preserved box of scaffold was 100%, 97.6%, 92.1% and 89.4% at each time point.
Conclusions: Neointimal hyperplasia of XINSORB scaffold was prominent at 3-
month. After that, LLL and %DS were noticeably reduced. LA at 18-month was
signiﬁcantly larger than that at 3-month with a constant scaffold area.
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Background: Ischemia-reperfusion injury (IRI) remains a major determinant of
mortality in acute myocardial infarction (AMI). Stromal cell-derived factor-1 (SDF-1)
is a chemokine that promotes myocardial salvage by activating cardioprotective
signaling via Akt, ERK, and STAT-3. No studies have targeted initially reducing left
ventricular stroke work (LVSW) to limit IRI in AMI. The Impella CP axial-ﬂow pump
reduces LVSW. We tested the hypothesis that ﬁrst reducing myocardial work and
delaying coronary reperfusion reduces infarct size by activating cardioprotective
signaling pathways.
Methods: AMI was induced by occlusion of the left anterior descending artery (LAD)
via angioplasty for 90 minutes in 50kg male Yorkshire swine (n¼5/group). In Group
1, the LAD was reperfused for 120 minutes. In Group 2, after 90 minutes of ischemia
the Impella CP device was activated and the LAD left occluded for an additional 60
minutes (150 minutes of LAD occlusion total), followed by 120 minutes of reperfu-
sion. The Impella CP was active throughout reperfusion. Western blot analysis
quantiﬁed myocardial kinase activity.September 13–17, 2014 j TCT Abstracts/New Devices and Innovation
www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMResults: Compared to Group 1, Group 2 had a reduced LVSW, LV end-diastolic
volume and end-diastolic pressure after reperfusion. Group 2 showed increased
expression of myocardial and circulating levels of SDF-1, compared to Group 1.
Myocardial levels of phosphorylated cardioprotective kinases: Akt, ERK, GSK3b and
STAT-3 were increased in Group2, compared to Group 1. TUNEL staining demon-
strated less cardiomyocyte apoptosis and levels of pro-apoptotic factors including
BCL-2 and Caspase-3 were lower in Group 2, compared to Group 1. Compared to
Group 1, the percent myocardial infarct size normalized to the area at risk (AAR) was
reduced in Group 2 (7313% vs 4215%, p¼0.02).
Conclusions: We report the potential beneﬁt of primarily unloading the heart and
delaying coronary reperfusion to salvage myocardium in AMI. This is the ﬁrst report
to demonstrate increased expression of SDF-1 and associated cardioprotective kinases
in response to acute mechanical unloading and delayed myocardial reperfusion. This
report is also the ﬁrst examine the impact of the Impella CP on cardioprotective
signaling in the heart.
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Background: Components of endovascular stents, heart valves and cardiac rhythm
devices are made using metal alloys, which are inherently thrombogenic. We have
developed a robust, hemocompatible plasma-activated coating (PAC) to covalently
bind biomolecules in their bioactive state to metallic surfaces. We then immobilised
plasmin, a major mediator of hemostasis, currently used clinically to disrupt clot
formation, and investigated its blood compatibility.
Methods: PAC was deposited onto stainless steel (SS) substrates in a purpose built
plasma polymerization chamber. Blood compatibility was assessed with heparanized
whole blood in in vitro assays of clotting under rocking and ﬂow conditions, while cell
studies used human coronary artery endothelial cells.
Results: Increasing concentrations of plasmin, 0.1 U, 1.0 U, and 10 U, were
covalently immobilized on PAC. Bioactivity was demonstrated using an established
enzymatic activity assay, while 10U plasmin coating was also found to support
endothelial cell proliferation, increasing 2.6-fold from day 3 to day 5 (p< 0.001). In
a whole blood adhesion assay, these surfaces demonstrated a dramatic reduction of
thrombus weight in a dose dependant manner, compared to SS controls. PAC alone
reduced thrombus weight 45.49.1%, but further reductions were observed for 0.1U
(62.36.4%), 1U (78.36.4%) and 10U (90.51.3%) plasmin, relative to SS (p<
0.001). Strikingly, the 10U plasmin surface signiﬁcantly reduced clot weight
97.71.3% in a modiﬁed chandler loop, relative to SS and PAC alone (p< 0.001).
Moreover, after freeze-drying and 14 weeks of storage, the reduction of thrombus
was persistent (94.68.3%) and not signiﬁcantly different from freshly prepared
surfaces, indicating retention of bioactivity. These ﬁndings were successfully
translated to a custom laser cut SS stent platform, demonstrating robust PAC
adhesion without delamination and similarly striking reductions in thrombus
formation.
Conclusions: Our PAC technology facilitates the covalent immobilization of plasmin,
which dramatically reduced clot formation relative to SS. This has profound potential
to improve the efﬁcacy of all metallic vascular implants, and particularly endovascular
stents.
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Background: Nitrite is a physiologically important nitric oxide (NO) storage inter-
mediate that is reduced to NO during cardiovascular disease states and serves a
cytoprotective function. We evaluated the effects of chronic administration of a novel,
sustained release formulation of sodium nitrite (SR-Nitrite, Theravasc, Inc.) on
circulating NO levels and coronary vascular function in a clinically relevant model of
metabolic syndrome (MetS).
Methods: MetS was generated in Ossabaw miniswine fed an atherosclerotic high-fat
diet (6 months) resulting in profound coronary vascular dysfunction. SR-Nitrite was
administered orally (80 mg/kg b.i.d.) for 3 wks. Plasma levels of nitrite and nitro-
sothiols (RSNO) were quantiﬁed at baseline and following SR-Nitrite. Left anterior
descending coronary arteries were isolated, suspended in organ chambers and iso-
metric tension acquired. Following pre-constriction with PGF2a, vascular relaxation
to sodium nitroprusside was evaluated.
Results: SR-Nitrite therapy increased plasma levels of nitrite (0.35  0.21 vs. 1.2 
0.75 mM; p¼0.02) and RSNO (10.7  2.4 vs. 25.4  5.1 nM; p¼0.03) after 3 wks of
treatment compared to placebo. SR-Nitrite treatment resulted in signiﬁcant improve-
ment in vasoreactivity to SNP with maximal relaxation of 39  10% vs. 72  10 %,
(p< 0.05).JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/NeConclusions: In a clinically relevant large animal model of MetS, treatment with SR-
Nitrite increased NO bioavailability and improved ex vivo coronary artery dilation.
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Background: Vascular healing after drug-eluting stent implantation (DES) has been
shown to be an important determinant of PCI-related clinical outcomes. While lag of
endothelialization and increased inﬂammation were reported to cause delayed arterial
healing in ﬁrst generation DES, it has yet to be determined if this relationship also
exists for contemporary DES and fully resorbable everolimus-eluting scaffolds.
Methods: Twenty rabbits received thin-strut bioerodable polymer everolims-eluting
stents (SynergyTM [Boston Scientiﬁc]), thick-strut bioerodable polymer biolimus-
eluting stents (BioMatrixTM [Biosensors]), and thick-strut fully resorbable scaffolds
(Absorb [Abbott Vascular]) in the iliac arteries for 14 and 28 days, respectively (n¼6
for each stent type at 14 days, n¼4 at 28days). Endothelial cell coverage was assessed
using scanning electron microscopy (SEM) and confocal microscopy (CM) following
staining for the endothelial marker CD31/PECAM-1 and RAM11-positive monocytes.
Results: Endothelial coverage was greatest in Synergy (14days, 27%; 28days, 86%)
followed by BioMatrix (14days, 20%; 28days, 65%) and signiﬁcantly less in Absorb
(14 days, 1%; 28 days, 13%) by SEM (14days, P¼0.005; 28days, P¼0.0001,
respectively). The percentage of CD31/PECAM-1 positive endothelial cells above
struts was similar between BioMatrix (17.3%) and Synergy (13.3%), and signiﬁcantly
less in Absorb (0.5%) (P¼0.023), while RAM11 positive macrophage area was
similar between BioMatrix (0.16 mm2) and Synergy (0.17 mm2) and both were
signiﬁcantly less than with Absorb (2.47 mm2) at 28 days (P¼0.0007).
Conclusions: Thin-strut bioerodable polymer everolimus-eluting stents exhibited
superiority with respect to re-endothelialization as compared to thick-strut bioerodable
polymer biolimus-eluting stents and fully resorbable scaffolds, while monocyte
adherence was greatest in the latter. These ﬁndings conﬁrm substantial differences in
vascular healing among contemporary DES and bioresorbable scaffolds.
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Background: Previous preclinical experience showed that polymer-coatings of drug
eluting stents (DES) lower the predisposition for stent thrombosis compared to bare
metal stents. It remains unclear whether relevant differences exist in acute thrombo-
genicity particularly between current permanent and biodegradable polymers used in
clinical practice.
Methods: A porcine ex vivo carotid to jugular arteriovenous shunt model involving a
test circuit of three in-line stents, was used to test thrombogenicity. The permanent
ﬂuoropolymer XIENCE Xpedition everolimus-eluting stent (XIENCE, Abbott
Vascular) (n¼24 stents) was compared with 4 CE-marked DES with biodegradable
polymer coatings i) BioMatrix Flex (Biosensors) ii) Nobori (Terumo), iii) Orsiro
(Biotronik AG), and iv) Synergy (Boston Scientiﬁc) (n¼6 each). After 1h of cir-
culation, platelet adherence in whole mount stents was identiﬁed by immunoﬂuo-
rescent staining against dual platelet markers (CD61/CD42b) and imaged and
quantiﬁed under confocal microscopy.
Results: XIENCE showed the least area occupied by thrombus compared to the other
4 DES, with a signiﬁcant difference compared to BioMatrix Flex (p< 0.001) and
Synergy (p< 0.001) (Figure). The number of platelet aggregation clots was also thew Devices and Innovation B127
